Table 2.

Proportion of patients undergoing colectomy after specific drug switches, evaluated at 1 year after switch in each sequence

	Colectomy after First Switch		Colectomy after Second Switch		Colectomy after Third Switch
	n	%	n	%	n	%
anti-TNF to anti-TNF	236/1895	12	32/193	17	3/27	11
anti-TNF to vedolizumab	103/980	11	44/251	18	5/29	17
anti-TNF to tofacitinib	7/101	7	5/29	17	2/17	12
anti-TNF to ustekinumab	5/107	5	2/41	5	1/7	14
Vedolizumab to other	39/214	18	25/145	17	17/58	29
Tofacitinib to other	1/17	6	6/24	25	2/15	13
Ustekinumab to other	1/11	9	2/12	17	0/8	0

Anti-tumor necrosis factor alpha (Anti-TNF)

Note: tofacitinib approved for ulcerative colitis in 2018, ustekinumab approved for ulcerative colitis 2019